You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Checkpoint Kinase 1 Inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

Cervical Cancer, Cervical Carcinoma Trial in Guangzhou (Zimberelimab, Lenvatinib)

Not yet recruiting
  • Cervical Cancer
  • Cervical Carcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

Not yet recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • San Antonio, Texas
    Next Oncology
Aug 9, 2022

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Safety of ICIs and TKIs Therapy for HCC

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Lenvatinib Oral Product
  • +2 more
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Jun 11, 2022

Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 Trial

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 17, 2022

High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)

Recruiting
  • High-Risk Localized Soft Tissue Sarcoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2023

Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,

Completed
  • Gastrointestinal Tumor
  • Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
  • tislelizumab (BeiGene, China) combined with PD-1 inhibitor
  • Hangzhou, China
    Zhejiang Hospital
Sep 1, 2023

NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)

Not yet recruiting
  • NSCLC Associated With Leptomeningeal Metastases
  • Tislelizumab, pemetrexed
  • (no location specified)
Nov 21, 2023

Development ofEORTC Immune Checkpoint Inhibitor-specific Quality

Recruiting
  • Cancer
  • +2 more
    • Paris, France
      Institut Curie
    Nov 2, 2022

    Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint

    Active, not recruiting
    • Recurrent Nasopharyngeal Carcinoma
    • +2 more
    • PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
    • Guangzhou, Guangdong, China
      Yanqun Xiang
    Sep 5, 2022

    Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

    Not yet recruiting
    • Nasopharyngeal Carcinoma
    • +3 more
    • Intensity Modulated Radiation Therapy
    • +3 more
    • (no location specified)
    Jul 11, 2023

    Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

    Not yet recruiting
    • Metastatic Pancreatic Cancer
    • Durvalumab
    • Rintatolimod
    • Rotterdam, Zuid-Holland, Netherlands
      Erasmus MC
    Jun 23, 2023

    Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma

    Not yet recruiting
    • Anatomic Stage III Breast Cancer AJCC v8
    • +4 more
    • Biopsy
    • +5 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Feb 14, 2023

    Gut and Tumor Microbiome in Advanced ER-positive and

    Not yet recruiting
    • Breast Cancer
    • Melanoma
    • Observation
    • (no location specified)
    Nov 6, 2023

    Pre-transplant ICI Exposure and Post-transplant Graft Rejection

    Recruiting
    • Graft Rejection
    • +3 more
    • Immune checkpoint inhibitor
    • Guangzhou, Guangdong, China
      Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
    Jun 21, 2023

    Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)

    Recruiting
    • Solid Tumors, Adult
    • NECVAX-NEO1
    • Kaunas, Lithuania
      Elona Juozaityte
    May 16, 2022

    Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

    Active, not recruiting
    • Neurofibromatosis 1
    • Neurofibroma Plexiform
    • Shanghai, China
    • +1 more
    Jan 13, 2023

    Solid Tumor, Adult Trial in Orlando, Cincinnati (ADA-011, PD(L)-1 inhibitor)

    Recruiting
    • Solid Tumor, Adult
    • Orlando, Florida
    • +1 more
    Jan 6, 2023

    Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

    Recruiting
    • Neurofibromatosis 1
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

    Not yet recruiting
    • Metastatic Melanoma
    • Advanced Melanoma
    • San Francisco, California
      University of California, San Francisco
    Jan 13, 2023

    Metastatic Solid Tumor, NSCLC, Gastric Cancer Trial (RO7496353, Atezolizumab, Capecitabine)

    Not yet recruiting
    • Metastatic Solid Tumor
    • +3 more
    • (no location specified)
    May 22, 2023

    Gastrointestinal Cancer Trial in New York, Providence (Cobimetinib, Hydroxychloroquine, Atezolizumab)

    Active, not recruiting
    • Gastrointestinal Cancer
    • New York, New York
    • +1 more
    Nov 29, 2022